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Objectives: Group B Streptococcus (GBS) increasingly causes invasive disease in non-pregnant adults, particularly
in elderly persons and those with underlying diseases. Combination therapy with penicillin plus gentamicin
has been suggested for periprosthetic joint infection. The postulated synergism of this combination is based on
experiments with planktonic bacteria. We aimed to assess the efficacy of this combination against sessile
bacteria.
Methods: Four different GBS strains were used. We compared results of MICs with those of minimal biofilm eradi-
cation concentrations (MBECs), applied chequerboard assays to the MBEC device and calculated the fractional
inhibitory concentration index. Synergism was evaluated with time–kill assays against bacteria adherent to ce-
ment beads, using penicillin (0.048, 0.2 and 3 mg/L), gentamicin (4 and 12.5 mg/L) and a combination thereof.
Results were evaluated via colony counting after sonication of beads and scanning electron microscopy.
Results: MBEC/MIC ratios were 2000–4000 for penicillin and 1–4 for gentamicin. In chequerboard assays, syner-
gism was observed in all four isolates. In time–kill assays, penicillin and 12.5 mg/L gentamicin showed synergism
in two isolates. In the other two isolates 12.5 mg/L gentamicin alone was as efficient as the combination
therapy.
Conclusions: These in vitro investigations show activity of 12.5 mg/L gentamicin, alone or as an adjunct to peni-
cillin, against four strains of biofilm GBS. This concentration cannot be achieved in bone with systemic adminis-
tration, but can be reached if administered locally. The combination of systemic penicillin plus local gentamicin
indicates a potential application in orthopaedic-device-associated GBS infections. Studies with a larger number
of strains are required to confirm our results.
Introduction
Group B Streptococcus (GBS) increasingly causes invasive GBS dis-
ease in non-pregnant adults, particularly in elderly persons and
those with underlying diseases. Several reports have highlighted
the role of GBS in periprosthetic joint infections (PJIs),1 GBS being
a frequently found species among all streptococcal PJIs.
Treatment concepts are not established, but combination ther-
apy with penicillin plus gentamicin has been suggested during
the first 2 weeks of treatment.2 Similar recommendations have
been made for infective endocarditis (IE).3 These suggestions
were derived from in vitro studies showing synergism against
planktonic bacteria with these antibiotics.4 Here, we investigated
this postulated synergism against four different strains of GBS in
sessile form.
Methods
For this study, four strains were used. We used two clinical isolates obtained
from patients with PJI (BE07-1b) and IE (BE05-1). NEM316 (a frequently
used strain for laboratory experiments5) and Col2 (BE12-2, a strain obtained
from a colonized woman that showed high biofilm production on crystal
violet staining) were used as controls. The MIC and minimal biofilm eradica-
tion concentration (MBEC) were measured via the microbroth dilution
method. Penicillin (benzylpenicillin sodium, Grünenthal Pharma AG, Mitlödi,
Switzerland) and gentamicin (Salutas Pharma, Holzkirchen, Germany) were
supplied from the clinical pharmacy of the University Hospital (Bern,
Switzerland). Chequerboard assays were applied to the MBEC device
(Innovotech Inc., Edmonton, Alberta, Canada) and the fractional inhibitory
concentration index (FICI) was calculated. A synergistic effect was defined
as FICI 0.5. In addition, synergism was evaluated with time–kill assays
against bacteria adherent to a foreign body, as described previously.6
VC The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
For Permissions, please email: journals.permissions@oup.com.
1 of 4
J Antimicrob Chemother
doi:10.1093/jac/dkw447
 Journal of Antimicrobial Chemotherapy Advance Access published December 20, 2016
 at E
-L
ibrary Insel on January 3, 2017
http://jac.oxfordjournals.org/
D
ow
nloaded from
 
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
9
2
3
8
1
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
Table 1. Antimicrobial susceptibilities (mg/L) and FICIs
Isolate MIC determined by microbroth dilution MBEC
PEN GEN PEN GEN FICI
PJI 0.03 (0.016–0.04) 23.4 (15.6–31.25) 75 (75–150) 31.25 (15.6–31.2) 0.23 (0.06–0.38)
IE 0.04 (0.016–0.04) 15.6 (7.8–15.6) 75 (75–300) 62.5 (31.2–62.5) 0.39 (0.18–0.75)
NEM316 0.04 (0.032–0.04) 15.6 (7.8–15.6) 18.7 (9.4–18.7) 15.6 (7.8–15.6) 0.11 (0.11–0.11)
Col2 0.02 (0.016–0.04) 7.8 (7.8–15.6) 37.5 (4.7–37.5) 7.8 (7.8–7.8) 0.38 (0.38–0.5)
PEN, penicillin; GEN, gentamicin.
All measurements were repeated three or more times. Results are presented as median and range.
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Figure 1. Time–kill assays of sessile GBS. After antibiotic exposure for 12 h, bacteria were dislodged from cement beads via sonication and cfu
counted. The following strains were used: (a) IE, a GBS strain obtained from a patient with IE; (b) PJI, a GBS strain obtained from a patient with PJI;
(c) Col2, a GBS strain obtained from a vaginally colonized woman (control strain); and (d) NEM316, control strain.5 Bacteria adhered to a cement bead
for biofilm formation for 24 h. An asterisk indicates the limit of detection. The data shown represent means with standard deviations. T0, timepoint 0;
PEN, penicillin; GEN, gentamicin.
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In brief, cement beads (Biomet, Dordrecht, the Netherlands) were incu-
bated with 105–106 cfu/mL GBS for 24 h to form a biofilm and then washed
to remove non-sessile bacteria. Then the biofilm was challenged with anti-
biotics for 12 h. Antimicrobial concentrations were as follows: penicillin,
0.048, 0.2 and 3 mg/L; gentamicin, 4 and 12.5 mg/L; and combinations
thereof. The rationale for selecting these penicillin concentrations was
based on the following arguments: (i) 0.048 mg/L is a concentration that
was considered as an approximation of 1MIC for all four strains (Table 1);
(ii) 3 mg/L is a penicillin serum concentration in adults 4 h after completion
of intravenous administration of 5 million IU of penicillin;7 and (iii) 0.2 mg/L
is an extrapolation from serum trough levels (3 mg/L)7 to 15% bone pene-
tration of penicillin (i.e. bone–serum ratio in humans 0.1–0.2).8 Gentamicin
concentrations were selected on the basis of peak serum levels in adults
after intravenous administration of 1 mg/kg (4 mg/L in serum) or 3 mg/kg
(12.5 mg/L in serum) body weight (bw).9 After antibiotic exposure, biofilm
was dislodged via sonication (3210, Branson Ultrasonics Corporation,
Geneva, Switzerland) at 40 kHz for 5 min and dilutions were plated for as-
sessing the number of cfu.
Synergy was defined as a 100-fold (2 log) increase in killing at 24 h
with the combination therapy in comparison with the most active single
drug. Colony count results were paralleled by imaging with a scanning elec-
tron microscope. All assays were repeated at least three times.
Results
MIC, MBEC and FICI results are presented in Table 1. Penicillin
MBEC/MIC and gentamicin MBEC/MIC ratios were 2000–4000 and
1–4, respectively. In chequerboard assays, synergism of penicillin
plus gentamicin was observed in all isolates. Time–kill assay re-
sults are presented in Figure 1(a–d). With penicillin monotherapy,
the colony count reduction ranged from <0.5 to 2.5 logs. There
was an insignificant tendency that the higher the penicillin con-
centration, the more effective the killing of sessile GBS. In the two
control strains (Col2 and NEM316), a gentamicin concentration of
12.5 mg/L alone reduced the number of cfu by >3 logs (Figure 1c
and d). This was not observed in the two clinical strains (IE and
PJI) or when 4 mg/L gentamicin alone was used. In penicillin/gen-
tamicin combination assays using 4 mg/L gentamicin, >3 log cfu
reduction was only seen in one strain (IE; Figure 1a) and when
3 mg/L penicillin was used. The most effective combination was
seen with penicillin (all three concentrations) plus 12.5 mg/L gen-
tamicin. The mathematical criteria for synergism were fulfilled in
two clinical isolates (PJI and IE). In the control isolates, Col2 and
NEM316, this was not the case, because the effect of 12.5 mg/L
gentamicin alone was similar to that of penicillin plus 12.5 mg/L
gentamicin. In accordance with the time–kill assay results, scan-
ning electron microscopy showed eradication of biofilm from the
cement beads after IE and PJI had been treated with 0.2 mg/L
penicillin plus 12.5 mg/L gentamicin (Figure 2).
Discussion
Our investigations confirm the results of a previous study on ses-
sile bacteria, showing a high penicillin MBEC/MIC ratio and a low
aminoglycoside MBEC/MIC ratio.10 Reduction of b-lactam MBEC
after adding gentamicin has been observed in some enterococ-
cal isolates.11 The results suggest a variability of biofilm suscep-
tibility to antibiotics between each strain that is difficult
to assess with the measurement of MBECs only. Nonetheless,
these data indicate that gentamicin (alone or in combination
therapy) at a sufficiently high concentration has activity against
biofilm GBS, provided that there is no high-level gentamicin
resistance.12
In clinical practice, gentamicin can be administered at 3 mg/kg
bw in a single dose or divided into two to three doses per day (i.e.
21.5 or 31 mg/kg bw). Our investigations showed marked
killing rates of adherent bacteria when we used 12.5 mg/L genta-
micin, corresponding to the peak serum concentration after single-
dose administration in adults (i.e. 13 mg/kg bw). The translation
of these results into clinical practice requires caution. It is unknown
T0 +12 h
IE
Col2
10 µm
Prior to antibiotic
treatment
PEN 0.2 mg/L GEN 12.5 mg/L PEN 0.2 mg/L +
GEN 12.5 mg/L
Positive control
Figure 2. Scanning electron microscopy of cement beads inoculated with GBS biofilm. GBS IE (upper row) represents clinical isolates and Col2 (lower
row) is a control isolate. Twenty-four hours after inoculation with GBS, and prior to antibiotic exposure, biofilm is visible on cement beads (T0, time-
point 0). Penicillin (0.2 mg/L) alone shows little effect in biofilm killing after 12 h of antibiotic exposure (second column from left). Gentamicin
(12.5 mg/L) alone markedly reduced the biofilm of GBS Col2, but not of GBS IE (third column from left). The anti-biofilm effect in clinical and control
isolates with 0.2 mg/L penicillin plus 12.5 mg/L gentamicin is shown in the second column from right. The positive controls (GBS strains without anti-
biotic exposure) show continuous growth in biofilm (right column).
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how the bacterial state cultured on cement beads can be com-
pared with endocardial vegetation on a heart valve or a biofilm in
PJI. The killing rates of bacteria presented here are based on
exposure to a single dose and antibiotics are not—as they are
in vivo—metabolized. In other words, the effect of concentration
fluctuation in a patient could not be reflected in this in vitro study,
since fixed antibiotic concentrations were used for 12 h. However,
we used penicillin concentrations that are considered as trough
levels in humans (i.e. 3 mg/L in serum and 0.2 mg/L in bone). No
recommendation about the duration of aminoglycoside treatment
can be made. A retrospective study on GBS IE indicated that ami-
noglycoside treatment beyond 7 days had a higher heart failure
rate and is likely not beneficial.13 The expanding population
affected by invasive GBS disease, namely, elderly persons and pa-
tients with comorbidities, is more prone to the nephrotoxicity of
aminoglycosides. Of note, the combination of penicillin (0.2 or
3 mg/L) plus gentamicin (12.5 mg/L) is unlikely to occur in patients
treated for GBS PJI because—considering the recommended dos-
ing—penicillin concentrations rarely fall below 3 mg/L in serum or
0.2 mg/L in bone,7 and a gentamicin concentration of 12.5 mg/L is
not achieved in bone when administered intravenously. Moreover,
in infections affecting tissues or biological fluids the pH is acidic.
Low pH increases MICs of aminoglycosides for Gram-positive
cocci.14 Hence, the efficacy of systemically administered amino-
glycosides against Gram-positive cocci in bone is uncertain.
Penicillin (both concentrations, 0.2 and 3 mg/L) plus 12.5
mg/L gentamicin is possible in bone when penicillin is given sys-
temically and gentamicin locally. Degradable drug delivery sys-
tems in bone have shown high levels of gentamicin release into
the bone (e.g. >600 mg/L during the initial 48 h).15 At these con-
centrations, antibacterial activity is likely, even in a low-pH milieu.
Our in vitro investigations show activity of gentamicin—alone
for two control strains or as an adjunct to penicillin for two clinical
strains—against biofilm GBS when a concentration of 12.5 mg/L,
but not 4 mg/L, is used. This concentration cannot be achieved in
bone with systemic administration, but can be reached if adminis-
tered locally. The translation of these findings into clinical practice
requires further studies with a higher number of strains and the
use of in vivo models. The combination of systemic penicillin plus
local gentamicin indicates a potential application in orthopaedic-
device-associated infections.
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